Onco360 Oncology Pharmacy

What Onco360 Oncology Pharmacy does

Onco360 is an independent oncology specialty pharmacy founded in 2003 and headquartered in Louisville, KY, that operates as a subsidiary of BrightSpring Health Services (Res-Care, Inc.). The company is 100% focused on oncology — deliberately not a general specialty pharmacy — and dispenses 160+ limited-distribution oncology therapies nationally through a network of URAC-, ACHC-, and NABP Digital-accredited pharmacies operating from seven U.S. locations (Louisville, New Hyde Park, Buffalo, Waltham, Houston, Woodridge, Scottsdale). It serves five customer segments: patients, physicians, pharmaceutical manufacturers, payers, and hospitals/health systems.

The company's core platform combines dispensing with clinical, financial, and digital services. Clinical care is led by Board-Certified Oncology Pharmacists (BCOPs) and oncology-specialized nurses (available 8am–8pm EST) and is delivered through Medication Therapy Management, Onco Care Coordinators (initial onboarding, insurance verification, monthly refill outreach), and Total Protocol Management that covers oral, injected, and infused regimens as a single source. Financial assistance is delivered by the OncoAdvocate team — 30+ associates that search for third-party funding multiple times daily — which the company reports drove zero out-of-pocket medication costs for 67% of patients in 2025. The myOnco360 Patient App + Portal (iOS/Android) provides 24/7 prescription history, real-time order tracking, funding information, payments, and DocuSign-based document signing; supporting infrastructure includes FedEx Priority Overnight shipping, e-prescribe under Oncomed (NPI# 1679618151), and in-house custom data and analytics for real-time clinical reporting.

Commercially, Onco360 generates revenue through (1) specialty pharmacy dispensing fees (transaction-fee model) paid by insurers, patients, and manufacturers, and (2) managed-services revenue from pharmaceutical manufacturer partnerships for limited-distribution drug commercialization, including preferred or sole national specialty pharmacy roles on flagship launches (e.g., Voydeya with Alexion, LIFYORLI with Corcept, UNLOXCYT with Sun Pharma). Go-to-market is enterprise field sales to physician offices, hospital systems, payers, and pharma manufacturers, complemented by referral channels (e-prescribe, fax, phone) and a marketing function driving digital patient engagement. The business has grown 600%+ by headcount since 2015 and was ranked #1 in patient and provider satisfaction by MMIT for Q3 2025, positioning Onco360 as the largest independent oncology pharmacy in the United States.

Name

Onco360 Oncology Pharmacy

Legal name

Res-Care, Inc., d/b/a BrightSpring Health Services

Website

https://onco360.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Onco360 is a Louisville, KY-based independent oncology specialty pharmacy, founded in 2003, that dispenses 160+ limited-distribution oncology therapies nationally to patients, physicians, pharma manufacturers, payers, and hospitals through Board-Certified Oncology Pharmacists. Subsidiary of BrightSpring Health Services.

Ownership category

akta.pro rank

Product category

Specialty Pharmacy Services

NAICS

Pharmacies and Drug Retailers (456110)

SIC

Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

Keywords

• Oncology pharmacy services
• Specialty medication dispensing
• Limited distribution drugs
• Cancer treatment support
• Clinical oncology services

Headquarters

HQ city

Louisville

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Specialty Pharmacy Dispensing: Dispensing oncology and complex disease medications; operates as independent specialty pharmacy serving patients nationally
2. Pharmaceutical Manufacturer Partnerships: Participation in limited distribution networks for pharmaceutical manufacturers; contracted as national or specialty pharmacy partner for specific drug therapies

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

Onco360 Oncology Pharmacy is an independent specialty pharmacy that is 100% focused on oncology, dispensing oral, injected, and infused oncology and specialty disease medications nationally through a network of URAC-, ACHC-, and NABP Digital-accredited pharmacies. It combines dispensing with clinical counseling from Board-Certified Oncology Pharmacists, financial-assistance sourcing, insurance benefit verification, refill coordination, and the myOnco360 patient app/portal to manage the cancer-treatment journey for patients referred by physicians and hospitals.

Product overview

Onco360 is an independent oncology specialty pharmacy (not a general specialty pharmacy) that focuses exclusively on oncology pharmacy services. The company offers a unified platform combining dispensing services with clinical support, financial assistance, and patient engagement tools. The core product is the Onco360 Oncology Specialty Pharmacy service, which dispenses over 160 oncology and specialty therapies nationally. This is supported by the myOnco360 Patient App + Portal for patient self-service, the OncoAdvocate Team for financial assistance sourcing, Onco Care Coordinator Services for initial onboarding, Medication Therapy Management (MTM) for ongoing clinical counseling, and Total Protocol Management for comprehensive oral/injected/infused medication coverage. The company was founded in 2003 and is headquartered in Louisville, KY, dispensing nationally through its network of URAC-, ACHC-, and NABP Digital-accredited oncology pharmacies.

Differentiator

Problem solved

Functional benefit

Products and services

• Onco360 Oncology Specialty Pharmacy National independent oncology specialty pharmacy dispensing oral, injected, and infused oncology and complex-disease medications with personalized clinical support from Board-Certified Oncology Pharmacists, nurses, and specialists. For cancer patients referred by physicians and for the physicians, hospitals, payers, and pharma manufacturers who serve them.
• myOnco360 Patient App + Portal

Quantifiable outcome

• 67% of patients had zero out-of-pocket expenses for medication in 2025
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature5 records

Partnerships

20 partnerships are on record, tiered flagship, core and minor.

• Corcept TherapeuticsflagshipChannel Partner/ Reseller/ Distributor · 25 March 2026Onco360 selected as national pharmacy partner for LIFYORLI (relacorilant), indicated for treatment of platinum-resistant ovarian cancer. LIFYORLI is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA) for this indication. Partnership aims to support accessible and specialized oncology care.
• Sun PharmaceuticalsflagshipChannel Partner/ Reseller/ Distributor · 14 January 2026Onco360 selected as national pharmacy partner for UNLOXCYT (cosibelimab-ipdl), the first and only PD-L1 immune checkpoint inhibitor approved for metastatic or locally advanced cutaneous squamous cell carcinoma.
• Rigel PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 7 January 2026Onco360 partnered with Rigel Pharmaceuticals to add three therapies to its limited distribution portfolio: TAVALISSE (fostamatinib), GAVRETO (pralsetinib), and REZLIDHIA (olutasidenib).
• Bayer PharmaceuticalsflagshipChannel Partner/ Reseller/ Distributor · 20 November 2025Onco360 selected as national specialty pharmacy partner for HYRNUO (sevabertinib), FDA-approved for treating advanced non-small cell lung cancer patients with HER2 mutations.
• Kura OncologycoreChannel Partner/ Reseller/ Distributor · 14 November 2025Onco360 selected as national specialty pharmacy partner for Komzifti (ziftomenib), which treats adult AML patients with NPM1 mutations who have limited treatment options.
• Cycle PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 17 October 2025Onco360 selected as pharmacy partner for PHYRAGO (dasatinib), used to treat certain types of leukemia. Phyrago offers bioequivalent to Sprycel with additional benefits allowing co-administration with gastric acid disorder medications.
• Eli LillycoreChannel Partner/ Reseller/ Distributor · 26 September 2025Onco360 selected as specialty pharmacy partner for INLURIYO (imlunestrant), an oral treatment for certain breast cancer patients.
• SanoficoreChannel Partner/ Reseller/ Distributor · 2 September 2025Onco360 selected as national specialty pharmacy partner for WAYRILZ (rilzabrutinib), a treatment for certain immune conditions.
• Boehringer IngelheimcoreChannel Partner/ Reseller/ Distributor · 11 August 2025Onco360 selected as specialty pharmacy partner for HERNEXEOS (zongertinib), an oral treatment for HER2-mutated NSCLC.
• Jazz PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 7 August 2025Onco360 adds Modeyso (dordaviprone) to portfolio as national specialty pharmacy provider for oncology and rare cancer therapies.
• RegeneroncoreChannel Partner/ Reseller/ Distributor · 31 July 2025Onco360 selected as specialty pharmacy partner for LYNOZYFIC (linvoseltamab-gcpt), a bispecific antibody for multiple myeloma.
• BMScoreChannel Partner/ Reseller/ Distributor · 1 July 2025Onco360 selected as national specialty pharmacy for Augtyro (repotrectinib), a TKI for ROS1-positive NSCLC.
• Deciphera PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 19 June 2025Onco360 selected as national specialty pharmacy partner for QINLOCK (ripretinib), a treatment for GIST.
• Nuvation BiocoreChannel Partner/ Reseller/ Distributor · 11 June 2025Onco360 selected as national specialty pharmacy partner for IBTROZI (taletrectinib), a TKI for ROS1-positive NSCLC.
• Verastem OncologycoreChannel Partner/ Reseller/ Distributor · 12 May 2025Onco360 selected as national specialty pharmacy partner for AVMAPKI FAKZYNJA CO-PACK for KRAS G12C-mutated NSCLC.
• SpringWorks TherapeuticscoreChannel Partner/ Reseller/ Distributor · 12 February 2025Onco360 selected as national specialty pharmacy partner for GOMEKLI (mirdametinib), a treatment for NF1-associated plexiform neurofibromas.
• Handa TherapeuticsminorStrategic or Co-development PartnerCycle Pharmaceuticals partnered with Handa Therapeutics for PHYRAGO (dasatinib) development and distribution through Onco360.
• McKessoncoreChannel Partner/ Reseller/ DistributorDistribution partner for PHYRAGO (dasatinib) along with Onco360, Cencora, and Cardinal Health.
• CencoracoreChannel Partner/ Reseller/ DistributorDistribution partner for PHYRAGO (dasatinib) along with Onco360, McKesson, and Cardinal Health.
• Cardinal HealthcoreChannel Partner/ Reseller/ DistributorDistribution partner for PHYRAGO (dasatinib) along with Onco360, McKesson, and Cencora.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• CVS Caremark Specialty: CVS Caremark Specialty is a major PBM-affiliated specialty pharmacy offering oncology and complex therapy dispensing, with broader portfolio scale than Onco360 but competing for the same limited distribution and physician-driven referrals.
• AllianceRx Walgreens Prime: AllianceRx Walgreens Prime is a specialty and home delivery pharmacy joint venture with national reach across oncology, immunology, and rare disease — competing for manufacturer limited distribution contracts and payer networks.
• Optum Specialty Pharmacy (OptumRx): Optum Specialty Pharmacy, part of UnitedHealth Group, is a major PBM-affiliated specialty pharmacy playing in oncology and limited distribution, directly competing with Onco360 for manufacturer and payer contracts.
• Accredo (Express Scripts/Evernorth): Accredo is one of the largest specialty pharmacies in the U.S., part of Evernorth/Express Scripts, and competes with Onco360 across oncology and complex conditions — broader portfolio but the dominant incumbent in specialty pharmacy.

Direct peers

• Avella Specialty Pharmacy: Avella is an independent specialty pharmacy focused on oncology, immunology, and other complex therapies, dispensing nationally and competing head-to-head with Onco360 in manufacturer limited distribution contracts and physician referrals.
• CareMed Specialty Pharmacy: CareMed is a sister specialty pharmacy under the same BrightSpring Health Services parent as Onco360, operating in adjacent specialty therapy areas and competing in many of the same limited distribution drug partnerships.
• Biologics by McKesson: Biologics by McKesson is an oncology-focused specialty pharmacy dispensing limited distribution cancer therapies — directly comparable to Onco360 in product scope, patient support services, and pharma manufacturer partnership model.
• Kroger Specialty Pharmacy: Kroger Specialty Pharmacy is an oncology-focused specialty pharmacy dispensing limited distribution cancer therapies, offering comparable clinical and financial patient support services to Onco360's model.
• PantherRx Rare: PantherRx Rare is a specialty pharmacy focused on oncology and rare disease therapies, competing for limited distribution wins and high-touch clinical services similar to Onco360's Total Protocol Management model.
• US Specialty Care (USSC): US Specialty Care is an oncology-focused specialty pharmacy dispensing limited distribution cancer therapies nationally, providing clinical and financial support services directly comparable to Onco360.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Onco360
• LinkedInlinkedin.com/company/oncomed-oncology-pharmacy
• Instagraminstagram.com/onco360

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Onco360 Oncology Pharmacy